Citizens JMP Reiterates Market Outperform Rating on Blueprint Medicines (BPMC)
Tweet Send to a Friend
Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $125.00 price target on Blueprint Medicines (NASDAQ: BPMC).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


